ITTO20020340A0 - Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato. - Google Patents

Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato.

Info

Publication number
ITTO20020340A0
ITTO20020340A0 IT2002TO000340A ITTO20020340A ITTO20020340A0 IT TO20020340 A0 ITTO20020340 A0 IT TO20020340A0 IT 2002TO000340 A IT2002TO000340 A IT 2002TO000340A IT TO20020340 A ITTO20020340 A IT TO20020340A IT TO20020340 A0 ITTO20020340 A0 IT TO20020340A0
Authority
IT
Italy
Prior art keywords
humanized
localization
biotinylated antibody
her2 receptor
her2
Prior art date
Application number
IT2002TO000340A
Other languages
English (en)
Inventor
Giovanni Bussolati
Anna Sapino
Original Assignee
Biother Di Contardi Gabriella
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biother Di Contardi Gabriella filed Critical Biother Di Contardi Gabriella
Priority to IT2002TO000340A priority Critical patent/ITTO20020340A1/it
Publication of ITTO20020340A0 publication Critical patent/ITTO20020340A0/it
Priority to EP03008916A priority patent/EP1357132A3/en
Priority to US10/417,336 priority patent/US20040110239A1/en
Publication of ITTO20020340A1 publication Critical patent/ITTO20020340A1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015Breast
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IT2002TO000340A 2002-04-19 2002-04-19 Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato. ITTO20020340A1 (it)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IT2002TO000340A ITTO20020340A1 (it) 2002-04-19 2002-04-19 Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato.
EP03008916A EP1357132A3 (en) 2002-04-19 2003-04-16 Detection of the her2 receptor by means of biotinylated humanized antibody
US10/417,336 US20040110239A1 (en) 2002-04-19 2003-04-17 Detection to the HER2 receptor by means of biotinilated humanized antibody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2002TO000340A ITTO20020340A1 (it) 2002-04-19 2002-04-19 Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato.

Publications (2)

Publication Number Publication Date
ITTO20020340A0 true ITTO20020340A0 (it) 2002-04-19
ITTO20020340A1 ITTO20020340A1 (it) 2003-10-20

Family

ID=27639017

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2002TO000340A ITTO20020340A1 (it) 2002-04-19 2002-04-19 Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato.

Country Status (3)

Country Link
US (1) US20040110239A1 (it)
EP (1) EP1357132A3 (it)
IT (1) ITTO20020340A1 (it)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102580084B (zh) 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
PL2171090T3 (pl) 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
CA2713137C (en) 2008-01-25 2017-10-24 Hadasit Medical Research Services And Development Ltd. Targeting of innate immune response to tumor site
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
CN102421448A (zh) 2009-05-29 2012-04-18 霍夫曼-拉罗奇有限公司 Her2信号传导调控剂在表达her2的胃癌患者中
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
MX2014001766A (es) 2011-08-17 2014-05-01 Genentech Inc Anticuerpos de neuregulina y sus usos.
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
BR112014012979A2 (pt) 2011-11-30 2020-10-20 Genentech, Inc. mutações erbb3 em câncer
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
US20130259867A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783404A (en) * 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
CN100340575C (zh) * 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
MXPA02000962A (es) * 1999-07-29 2002-07-02 Medarex Inc Anticuerpos monoclonales humanos para her2/neu.

Also Published As

Publication number Publication date
EP1357132A2 (en) 2003-10-29
ITTO20020340A1 (it) 2003-10-20
US20040110239A1 (en) 2004-06-10
EP1357132A3 (en) 2003-11-19

Similar Documents

Publication Publication Date Title
ITTO20020340A0 (it) Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato.
LT3421498T (lt) Monokloniniai antikūnai prieš klaudiną-18, skirti vėžio gydymui
EP3929214A4 (en) ANTIBODY OR CHIMERIC ANTIGEN RECEPTOR DIRECTED AGAINST CLAUDIN 18.2
ATE545656T1 (de) Humanisierte antikörper, die beta amyloid-peptid erkennen
LTC2567976I2 (lt) Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui
NL1027975A1 (nl) Antilichamen tegen MAdCAM.
CY2012019I1 (el) Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20
IL243914A0 (en) Antibodies against vegf
DK2019840T3 (da) Antagonist anti-human CD40 monoklonalt antistof.
NL1027009A1 (nl) Antilichamen tegen M-CSF.
CR9253A (es) Fijacion de la dosificacion de anticuerpos her
IL165193A0 (en) Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
ITRM20040362A1 (it) Sistema per la realizzazione di costruzioni complesse.
NO20054351D0 (no) Monoklonalt antistoff og hybridom som produserer dette
NO20053400D0 (no) Fremgangsmate for fremstilling av etylenoksid.
EP1461001A4 (en) ASSOCIATED WITH CANCER EPITOP
BRPI0509495A2 (pt) anticorpo humanizado
FI20020807A0 (fi) Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita
ES1058780Y (es) Brida de union autoblocante.
ATE535259T1 (de) Immunogener, monoklonaler antikörper
EP2087103A4 (en) Cancerous disease modifying antibodies
ITMO20030359A1 (it) Sistema per produrre un materiale scorrevole.
AU2003236346A1 (en) Monoclonal antibody neutralizing megsin
ITMI20022132A1 (it) Dispositivo per la produzione di un velo cucito.
ZA200906225B (en) Cancer disease modifying antibody 010207-01 produced by hybridoma cell line AR51A630.3